Investor relations

IDEAYA Biosciences to Participate in Investor Relations Events

Strategic Insights

Oct 26, 2025 — 1 min read

IDEAYA Biosciences, a precision medicine oncology company, will participate in two upcoming investor relations events. The company will host a fireside chat at Citi's 2025 SMID Cap Biopharma Call Series on November 6, 2025, and another at the Jefferies Global Healthcare Conference in London on November 18, 2025. These events aim to showcase the company's progress in developing targeted therapeutics for cancer. In a recent press release, IDEAYA Biosciences highlighted its commitment to transforming cancer treatment through precision medicine.

Key Takeaways:

IDEAYA Biosciences will participate in two investor relations events: Citi's 2025 SMID Cap Biopharma Call Series and the Jefferies Global Healthcare Conference.
The company will host fireside chats at both events, featuring Yujiro S. Hata, President and Chief Executive Officer, and Maury Raycroft, Ph.D., a biotechnology equity research analyst.
IDEAYA's pipeline focuses on synthetic lethality and antibody-drug conjugates for molecularly defined solid tumor indications.
The company has a deep pipeline of product candidates, including those for molecularly defined solid tumor indications.
IDEAYA's mission is to bring forth the next wave of precision oncology therapies that are more selective, effective, and deeply personalized.
The company has robust internal capabilities in identifying and validating translational biomarkers.

Statistics:

2 investor relations events scheduled for participation by IDEAYA Biosciences.
2 fireside chats planned at the events, featuring CEO Yujiro S. Hata and analyst Maury Raycroft.
1 pipeline focused on synthetic lethality and antibody-drug conjugates.
30 days' availability of replay webcasts following live events.

Sources:

"IDEAYA Biosciences to Present at Citi’s 2025 SMID Cap Biopharma Call Series and Jefferies Global Healthcare Conference," IDEAYA Biosciences, October 27, 2025.
"Annual Report on Form 10-K," IDEAYA Biosciences, February 18, 2025.

The End of American Hypergrowth

For two centuries, the US economy grew by adding workers. That's over.

Healthcare's $5.3 Trillion Drag

How Medical Spending Became America's Biggest Productivity Tax

Breakthrough in Nanotechnology: Electromagnetic Shock Treatment Shows Promise

Researchers at the Wuhan University of Technology in China have made significant progress in the field of nanotechnology, specifically in the area of nanoindentation. A novel electromagnetic shock treatment (EST) method has been developed to enhance the microscale mechanical properties of a titanium alloy, with promising results obtained through array-based

Gut Microbiota Plays Crucial Role in Immunotherapy Success for Colon Cancer Patients

Research investigators at the Zhengzhou Central Hospital Affiliated to Zhengzhou University have made groundbreaking discoveries on the role of gut microbiota in determining the efficacy of immunotherapy for colon cancer patients. The study, which was recently published in Biochimica et Biophysica Acta, reveals that specific bacterial species and microbial metabolites

Read more

The End of American Hypergrowth

Healthcare's $5.3 Trillion Drag

Breakthrough in Nanotechnology: Electromagnetic Shock Treatment Shows Promise

Gut Microbiota Plays Crucial Role in Immunotherapy Success for Colon Cancer Patients